Vineet Joag, Sathi Wijeyesinghe, J Michael Stolley, Clare F Quarnstrom, Thamotharampillai Dileepan, Andrew G Soerens, Jules A Sangala, Stephen D O'Flanagan, Noah V Gavil, Sung-Wook Hong, Siddheshvar Bhela, Sailaja Gangadhara, Eyob Weyu, William E Matchett, Joshua Thiede, Venkatramana Krishna, Maxim C-J Cheeran, Tyler D Bold, Rama Amara, Peter Southern, Geoffrey T Hart, Luca Schifanella, Vaiva Vezys, Marc K Jenkins, Ryan A Langlois, David Masopust
The magnitude of SARS-CoV-2-specific T cell responses correlates inversely with human disease severity, suggesting T cell involvement in primary control. Whereas many COVID-19 vaccines focus on establishing humoral immunity to viral spike protein, vaccine-elicited T cell immunity may bolster durable protection or cross-reactivity with viral variants. To better enable mechanistic and vaccination studies in mice, we identified a dominant CD8 T cell SARS-CoV-2 nucleoprotein epitope. Infection of human ACE2 transgenic mice with SARS-CoV-2 elicited robust responses to H2-Db /N219-227 , and 40% of HLA-A*02+ COVID-19 PBMC samples isolated from hospitalized patients responded to this peptide in culture...
January 13, 2021: Journal of Immunology